Zoetis Inc. is facing significant stock volatility, with shares declining 16.4% to $129.91, down 26.7% from its 52-week high. Despite the stock drop, the world's largest pure-play animal health company reported strong fiscal Q4 results, including $2.4 billion in revenue and a net income of $603 million, reflecting a 3% year-over-year growth. Analysts project a mean price target of $136.00, indicating a potential upside of 16.5%, while the company prepares for the upcoming Bank of America Securities 2026 Animal Health Summit.
“Zoetis’s shares · have sunk to · $129.91 · 16.4% loss”
“Zoetis · was spun off from · Pfizer · 2013”
“Zoetis · is the world's largest · pure-play animal health company”
“Zscaler (ZS) · offered · clarity on contribution · from its Red Canary acquisition versus its core op”
“Zoetis · focuses on · animal health · for livestock and companion animals”
“Zoetis · share price · recently closed at · US$131.10”
“Zoetis · was spun off from · Pfizer · 2013”
“Zoetis · is the world's largest · pure-play animal health company”
“Zoetis Inc. · is valued at · market capitalization · $54.4 billion”
“Zoetis stock · touched its 52-week high of · $177 · on Mar. 10, 2025”
“Zoetis stock · is down · 26.7% · from its 52-week high”
“Zoetis stock · has surged · 1.6% · over the past three months”